texas oncology more breakthroughs. more victories
I am a: Patient | Caregiver | Refering Physician
Request an Appointment

Fort Worth Clinical Trials

Texas Oncology cancer centers in Fort Worth participate in a wide range of clinical trials and ground-breaking cancer research paving the way for new breakthroughs in cancer care. If you are a Texas Oncology patient in the Fort Worth area, you may be able to take part in these innovative clinical trials. Learn more and see a full list of current trials.

Our cancer researchers in the Fort Worth area are involved in several types of clinical trials:

  • Prevention trials focused on preventing cancer or recurrence. Trials might focus on the use of vitamins, different medications or a change in diet or exercise to determine if the risk of developing cancer is lowered.
  • Screening trials focused on identifying and detecting cancer in people who do not exhibit symptoms of cancer.
  • Diagnostic trials determining how to identify cancers using new tests. These trials often involve participants who show signs or symptoms of a particular cancer.
  • Treatment trials designed to answer questions about new treatments, such as drugs, surgical procedures, vaccines, or therapies involving current cancer patients.

Benefits and Risks of Participating in Clinical Trials

Discuss the benefits and risks with your physician if you're interested in participating in a clinical trial or cancer research in the Fort Worth area. Benefits include being actively involved in your healthcare, getting access to new treatments and medical care, and helping to further medical research. Risks may include unpleasant or serious side effects, treatments that are ineffective, and trials which take more time than standard treatment.

Clinical Trial Eligibility

Your eligibility for a clinical trial depends on several criteria, including your age and sex, your cancer type and stage of the cancer, previous treatments, and your overall medical history. View the list below of open clinical trials and cancer research opportunities in the Fort Worth area and talk to you doctor to determine which clinical trial is right for you.

Anal Cancer

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Bladder Cancer

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: PH3 Atez Bladder Can CTDNA+ (IMvigor) View

Description: A PHASE III DOUBLE-BLIND MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY (BO42843)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Breast Cancer

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Ph3 GDC-9545+ Palbo +/- Letro HER2- BC View

Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: IV

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Carcinoid

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: III

Cervical Cancer

Title: PH3 adv CC View

Description: A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Colon Cancer

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Endometrial Cancer

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Esophageal Cancer

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Fallopian Tube Cancer

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Gastric Cancer

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Head and Neck Cancer

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I

Hematologic

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Leukemia

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Arlington Cancer Center North

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: III/IV

Lung Cancer

Title: A phase 3, open-label, 3-cohort randomized study of N-803 in combination with current standard of care vs standard of care as first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A phase 3, open-label, 3-cohort randomized study of N-803 in combination with current standard of care vs standard of care as first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 SAR408701 vs Doce NSCLC CEACAM5+ View

Description: Randomized Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (EFC15858)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PH3 Sac Gov vs Doce NSCLC View

Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Sac Gov vs Doce NSCLC View

Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Lymphomas

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: III

Title: PH3 R-CHOP +/- Acalab Tx Naive DLBCL View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Melanoma

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Myelodysplastic Syndrome

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Myelofibrosis

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Myelomas

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Neuroendocrine Tumors

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Ovarian Cancer

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Pancreatic Cancer

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington South

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Peritoneal Cancer

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Prostate Cancer

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph2 BMS986218 + Niv combo Doce met CRPC View

Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Rectal Cancer

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Sarcoma

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Sarcoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Solid Tumors

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Urothelial Cancer

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Texas Oncology-Arlington Cancer Center North

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: IV

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Arlington Cancer Center North

Phase: III/IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Texas Oncology-Arlington South

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington South

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: IV

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: III/IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Texas Oncology-Bedford

Title: A phase 3, open-label, 3-cohort randomized study of N-803 in combination with current standard of care vs standard of care as first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: IV

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: III/IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Sac Gov vs Doce NSCLC View

Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Texas Oncology-Fort Worth Cancer Center

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: PH3 Atez Bladder Can CTDNA+ (IMvigor) View

Description: A PHASE III DOUBLE-BLIND MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY (BO42843)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 GDC-9545+ Palbo +/- Letro HER2- BC View

Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH3 adv CC View

Description: A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III/IV

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 SAR408701 vs Doce NSCLC CEACAM5+ View

Description: Randomized Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (EFC15858)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH3 R-CHOP +/- Acalab Tx Naive DLBCL View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph2 BMS986218 + Niv combo Doce met CRPC View

Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Sarcoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Texas Oncology-Grapevine

Title: A phase 3, open-label, 3-cohort randomized study of N-803 in combination with current standard of care vs standard of care as first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: IV

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: III/IV

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PH3 Sac Gov vs Doce NSCLC View

Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

No Phase

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington South

Title: A Phase I/II randomized, double-blind, placebo-controlled trial(1-BETTER) examining XB2001 (anti-IL-1? True Humanantibody) in combination with ONIVYDE + 5-FU/LV(+folinic acid) in advanced pancreatic cancer

Indication: Pancreatic Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Title: FLEX Registry: Evaluate New Gene Express View

Description: MammaPrint BluePrint and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles: An Adaptable Registry (FLEX Registry)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Title: MYLUNG Study Part 2 View

Description: Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Prospective RWE Study (MYLUNG Consortium: Part 2)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: STAR: Ph1 FIH CUE101 Mono/Combo w/Pembro HNSCC View

Description: A Phase 1 First-In-Human Open-Label Dose Escalation and Expansion Study of CUE-101 Monotherapy in Second LIne and CUE-101 Combination Therapy with Pembrolizumab in First Line Patients with HPV16+ Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) (CUE-101-01)

Indication: Head and Neck Cancer

Location: Texas Oncology-Grapevine

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph1b Oral SM08502 CRPC CRC & NSCLC View

Description: A Phase 1b Open-Label Dose-Escalation Dose-Expansion Study Evaluating the Safety Pharmacokinetics and Efficacy of Orally Administered SM08502 Combined with Hormonal Therapy or Chemotherapy in Subjects with Advanced Solid Tumors (SM08502-ONC-03)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Title: Ph 1 PF-06821497 R/R SCLC CRPC & FL View

Description: C2321001: A PHASE I DOSE ESCALATION AND EXPANDED COHORT STUDY OF PF-06821497 IN THE TREATMENT OF ADULT PATIENTS WITH RELAPSED/REFRACTORY SMALL CELL LUNG CANCER (SCLC) CASTRATION RESISTANT PROSTATE CANCER (CRPC) AND FOLLICULAR LYMPHOMA (FL)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I

Phase I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Bladder Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR: Ph1/2 VS-6766 + Soto KRAS G12C NSCLC View

Description: A Phase 1/2 Study of VS-6766 in Combination with Sotorasib in Patients with KRAS G12C mutant Non-Small Cell Lung Cancer (NSCLC) (RAMP 203) (VS-6766-203)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph 1/2 ASTX727 Lower Risk MDS View

Description: A Randomized Open-Label Phase 1-2 Study of ASTX727 Low Dose (ASTX727 LD)Extended Schedule in Subjects with Lower Risk (IPSS Low or Intermediate-1)Myelodysplastic Syndromes (MDS) (ASTX727-03)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Neuroendocrine Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Rectal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Sarcoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR Ph1/2 MRTX849 Solids KRAS G12C View

Description: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation (849-001)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: I/II

Title: Ph1b/2 Surufatinib + Tislelizumab ST View

Description: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors (2020-012-GLOB1)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Arlington South

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Bedford

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: I/II

Title: STAR PH 2 Enfortumab in Urothelial Pts-Cohort L View

Description: A study of enfortumab vedotin (ASG-22CE) as monotherapy or in combination with other anticancer therapies for the treatment of urothelial cancer (SGN22E-002)

Indication: Urothelial Cancer

Location: Texas Oncology-Grapevine

Phase: I/II

Phase II

Title: A phase 3, open-label, 3-cohort randomized study of N-803 in combination with current standard of care vs standard of care as first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: A phase 3, open-label, 3-cohort randomized study of N-803 in combination with current standard of care vs standard of care as first-line treatment for patients with advanced or metastatic non-small cell lung cancer (NSCLC).

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: INCMGA00012 Endo Cancer View

Description: An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-Based Chemotherapy (INCMGA 0012-204/ POD1UM-204)

Indication: Endometrial Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Cin/Ramu/Pac HER2+ G/GEJ View

Description: A Phase 2 Multi-Center Open-Label Study of Cinrebafusp Alfa (PRS-343) in Combination with Ramucirumab and Paclitaxel in Patients with HER2-Positive Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination with Tucatinib in Patients with HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma(PRS-343-PCS_09_20)

Indication: Gastric Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Gastric Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Head and Neck Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 MRTX849 Pembro NSCLC KRAS View

Description: A Phase 2 Trial of MRTX849 Monotherapy and in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation (849-007)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Tomivosertib+Anti-PD-L1 NSCLC View

Description: A Randomized Double-Blind Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First-Line Therapy or When Progressing on Single-Agent First-Line Anti-PD-(L)1 Therapy (eFT508-0011)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 RMC-4630 Soto NSCLC KRAS-G12C View

Description: RMC-4630-03: A Phase 2 Open-Label Multicenter Study of the Combination of RMC-4630 and Sotorasib for Non-Small Cell Lung Cancer Subjects with KRAS G12C Mutation After Failure of Prior Standard Therapies

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR BV in pts w/1L cHL or PTCL View

Description: (SGN35-015) A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in older patients or patients with significant comorbidities ineligible for standard chemotherapy

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR: Zanu in Acala intolerant B-Cell View

Description: A Phase 2 Multicenter Single-arm Study of Zanubrutinib (BGB-3111) in Patients with Previously Treated B-Cell Lymphoma Intolerant of Prior Treatment with Ibrutinib and/or Acalabrutinib (BGB-3111-215)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: II

Title: PH2 Brentux+CHP In Tx Naive PTCL View

Description: A dual-cohort open-label phase 2 study of brentuximab vedotin and CHP (A+CHP) in the frontline treatment of subjects with peripheral T-cell lymphoma (PTCL) with less than 10% CD30 expression (SGN35-032)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Melanoma

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Selinexor vs PC MF View

Description: A PHASE 2 RANDOMIZED OPEN-LABEL MULTICENTER STUDY TO EVALUATE SAFETY AND EFFICACY OF SINGLE AGENT SELINEXOR VERSUS TREATMENT OF PHYSICIAN'S CHOICE IN PATIENTS WITH PREVIOUSLY TREATED MYELOFIBROSIS (XPORT-MF-035)

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Dara Lena Dexa (DRd) MM I View

Description: A phase II trial of daratumumab lenalidomide and dexamethasone (DRd) in combination with selinexor for patients with newly diagnosed multiple myeloma (USOR 20285)

Indication: Myelomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 VS-6766 Fak-Inhib LGSOC View

Description: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)(VS-6766-201) (GOG 3052)

Indication: Ovarian Cancer

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph1b/2 XMT-1536 ST NaPi2b View

Description: A Phase 1b/2 First-in-Human Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b (UPLIFT-Cohort 3) (MER-XMT-1536-1) (GOG-3048)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 AKT Pac vs Ova fall and Peri View

Description: An Open-Label Randomized Active-Controlled Phase II Clinical Study to Assess the Efficacy and Safety of Afuresertib Plus Paclitaxel Versus Paclitaxel in Patients with Platinum-Resistant Ovarian Cancer (LAE002INT2001)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: Ph2 BMS986218 + Niv combo Doce met CRPC View

Description: A Phase 2 Open-label Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination with Docetaxel in Participants with Metastatic Castration-resistant Prostate Cancer (CA022-009)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 Seribantumab NRG1 Fusion+ ST View

Description: CRESTONE: A Phase 2 Study of Seribantumab in Adult Patients with Neuregulin-1 (NRG1) Fusion Positive Locally Advanced or Metastatic Solid Tumors (ELVCAP-001-01)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 Bren Vedo + Pembro ST prior PD-1 View

Description: A phase 2 study of brentuximab vedotin in combination with pembrolizumab in subjects with metastatic solid malignancies after progression on prior PD-1 inhibitor treatment (SGN35-033)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Title: STAR Ph2 ZN-c3 Tumor DNA Repair CCGA View

Description: A Phase 2 Open-Label Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Subjects with Malignant Tumors Harboring DNA Repair and Cell Cycle Gene Alterations (ZN-c3-005 GOG 3066)

Indication: Solid Tumors

Location: Texas Oncology-Grapevine

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Arlington Cancer Center North

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Arlington South

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Bedford

Phase: II

Title: Ph2 TJ004309 + Atezo OC/ST View

Description: A PHASE 2 CLINICAL STUDY OF TJ004309 IN COMBINATION WITH ATEZOLIZUMAB (TECENTRIQ ®) IN PATIENTS WITH ADVANCED OR METASTATIC OVARIAN CANCERS AND SELECTED ADVANCED SOLID TUMORS (TJ004309STM103)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: II

Phase III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Anal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PH3 Atez Bladder Can CTDNA+ (IMvigor) View

Description: A PHASE III DOUBLE-BLIND MULTICENTER RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTI-PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY (BO42843)

Indication: Bladder Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 GDC-9545+ Palbo +/- Letro HER2- BC View

Description: (BO41843)A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF GDC-9545 COMBINED WITH PALBOCICLIB COMPARED WITH LETROZOLE COMBINED WITH PALBOCICLIB IN PATIENTS WITH ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 GDC-9545 ER+ HER2- BC (lidERA) View

Description: A PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTOR - POSITIVE HER2‑NEGATIVE EARLY BREAST CANCER (GO42784)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Nira Her2- triple- BC ctDNA (ZEST) View

Description: GSK 213831 : A RANDOMIZED PHASE 3 DOUBLE-BLINDED STUDY COMPARING THE EFFICACY AND SAFETY OF NIRAPARIB TO PLACEBO IN PARTICIPANTS WITH EITHER HER2-NEGATIVE BRCA-MUTATED OR TRIPLE-NEGATIVE BREAST CANCER WITH MOLECULAR DISEASE BASED ON PRESENCE OF CIRCULATING TUMOR DNA AFTER DEFINITIVE THERAPY

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 AZD9833 HR+/HER2- mBC -ctDNA (SERENA-06) View

Description: A Phase 3 double-blind randomized study to assess the efficacy and safety of switching to AZD9833 (an oral SERD) + CDK4/6 inhibitors (palbociclib or abemaciclib) vs continuing aromatase inhibitor + CDK4/6 inhibitors in patients with acquired ESR1 mutation without radiological progression during 1L treatment with AI + CDK4/6i for HR+/HER2- mBC-ctDNA guided early switch study (SERENA 6) (D8534C00001)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LY3484356 ER+ HER2- BC View

Description: EMBER-3: A Phase 3 Randomized Open-Label Study of Imlunestrant Investigator's Choice of Endocrine Therapy and Imlunestrant plus Abemaciclib in Patients with Estrogen Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated with Endocrine Therapy (J2J-OX-JZLC)

Indication: Breast Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LY3484356 vs PC +Fluv HR+ HER2- BC View

Description: postMONARCH: A Randomized Double-Blind Placebo-Controlled Phase 3 Study to Compare the Efficacy of Abemaciclib plus Fulvestrant to Placebo plus Fulvestrant in Participants with HR+ HER2- Advanced or Metastatic Breast Cancer Following Progression on a CDK4 & 6 Inhibitor and Endocrine Therapy (I3Y-MC-JPEF)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Carbo/Pac NCMGA00012 MSCC View

Description: A Phase 3 Global Multicenter Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Anal Canal Not Previously Treated With Systemic Chemotherapy (POD1UM-303/InterAACT 2) (INCMGA 0012-303)

Indication: Carcinoid

Location: Texas Oncology-Grapevine

Phase: III

Title: PH3 adv CC View

Description: A Randomized Phase 3 Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk Locally Advanced Cervical Cancer (KEYNOTE-A18 / ENGOT-cx11)

Indication: Cervical Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 MRTX849 Cetux KRAS G12C CC View

Description: A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (849-010)

Indication: Colon Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Sinti vs Placebo ESCC View

Description: A Multicenter Double-Blind Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Sintilimab vs. Placebo in Combination with Chemotherapy for First-Line Treatment of Unresectable Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma (ORIENT-15)CIBI308A301

Indication: Esophageal Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Fallopian Tube Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 SAR408701 vs Doce NSCLC CEACAM5+ View

Description: Randomized Open Label Phase 3 study of SAR408701 versus Docetaxel in Previously Treated metastatic non-squamous Non-Small Cell Lung Cancer patients with CEACAM5 positive tumors (EFC15858)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 EGFRm stage2/3b NSCLC View

Description: A Phase III Randomised Controlled Multi-centre 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive Resectable Non-small Cell Lung Cancer (NeoADAURA) (D516AC00001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 JNJ-61186372 Peme EGFR NSCLC View

Description: A Randomized Open-label Phase 3 Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy Compared with Carboplatin-Pemetrexed in Patients with EGFR Exon 20ins Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (61186372NSC3001)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Adj Selp St1B/3 RET+ NSCLC View

Description: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib following Definitive Locoregional Treatment in Participants with Stage IB-IIIA RET fusion-Positive NSCLC (LIBRETTO-432) (J2G-MC-JZJX)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Ami Laz EGFR-mut NSCLC View

Description: A Phase 3 Open-Label Randomized Study of Amivantamab and Lazertinib in Combination with Platinum-Based Chemotherapy Compared with Platinum-Based Chemotherapy in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure (61186372NSC3002)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: PH3 Sac Gov vs Doce NSCLC View

Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)

Indication: Lung Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Sac Gov vs Doce NSCLC View

Description: Open-label Global Multicenter Randomized Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) With Progression on or After Platinum-Based Chemotherapy and anti-PD-1/PD-L1 Immunotherapy (GS-US-577-6153)

Indication: Lung Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Tafa+ Lena R-CHOP B-Cell Lymp View

Description: MOR208C310: A Phase III multicenter randomized double-blind placebo-controlled trial comparing the efficacy and safety of tafasitamab plus lenalidomide in addition to R-CHOP versus R-CHOP in previously untreated high-intermediate and high-risk patients with newly-diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: III

Title: PH3 R-CHOP +/- Acalab Tx Naive DLBCL View

Description: A Phase 3 Randomized Double-Blind Placebo-Controlled Study of Acalabrutinib in Combination with Rituximab Cyclophosphamide Doxorubicin Vincristine and Prednisone (R-CHOP) in Subjects < or = 65 Years with Previously Untreated Non-Germinal Center Diffuse Large B-Cell Lymphoma (ACE-LY-312/ D8227C00001)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Bedford

Phase: III

Title: Ph3 LOXO-305 vs PC of BTK in MCL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)(LOXO-BTK-20019)

Indication: Lymphomas

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 LOXO-305 vs. InvChoice in CLL/SLL View

Description: A Phase 3 Open-Label Randomized Study of LOXO-305 versus Investigator's Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (LOXO-BTK-20020)

Indication: Lymphomas

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: Ph3 Vene Aza HR-MDS View

Description: A Randomized Double-Blind Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) (VERONA) (M15-954)

Indication: Myelodysplastic Syndrome

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR Ph3 Navi Ruxo Myelofibrosis View

Description: M16-191: A Randomized Double-Blind Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis (TRANSFORM-1)

Indication: Myelofibrosis

Location: Texas Oncology-Grapevine

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Ovarian Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PANOVA-3: 1L Gemcit + nab-pac pancreatic View

Description: PANOVA-3: Pivotal randomized open-label study of Tumor Treating Fields (TTFields 150kHz) concomitant with gemcitabine and nab-paclitaxel for front-line treatment of locally-advanced pancreatic adenocarcinoma (EF-27)

Indication: Pancreatic Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: Ph3 NIS793/Placebo+ Gem Nab-pac mPDAC View

Description: A randomized double-blind phase III study comparing NIS793 in combination with gemcitabine and nab-paclitaxel versus placebo combined with gemcitabine and nab-paclitaxel for first line treatment of metastatic pancreatic ductal adenocarcinoma (mPDAC) (CNIS793B12301)

Indication: Pancreatic Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: PH3 Pac-Carbo-Oreg EO FT or PC View

Description: A Phase 3 Double-Blind Placebo-Controlled Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin-Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) in Patients with Advanced Epithelial Ovarian Fallopian Tube or Peritoneal Carcinoma(FLORA-5)(QPT-ORE-005/GOG-3035)

Indication: Peritoneal Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Abi+/-Capi mHSPC CAPItello-281 View

Description: A Phase III Double-Blind Randomised Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer(mHSPC)Characterised by PTEN deficiency (CAPItello-281) D361BC00001

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Arlington South

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Bedford

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III

Title: STAR PH3 Nirap Abira HRR mCSPC View

Description: A Phase 3 Randomized Placebo-controlled Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)(67652000PCR3002)

Indication: Prostate Cancer

Location: Texas Oncology-Grapevine

Phase: III

Phase III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Arlington Cancer Center North

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Arlington South

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Bedford

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Fort Worth Cancer Center

Phase: III/IV

Title: STAR Ph3b ABL001 in CML-CP +/-T315i View

Description: An open label multi-center Phase IIIb study of asciminib (ABL001) monotherapy in previously treated patients with chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML)(CABL001AUS04)

Indication: Leukemia

Location: Texas Oncology-Grapevine

Phase: III/IV

Phase IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Arlington Cancer Center North

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Arlington South

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Bedford

Phase: IV

Title: Registry study with Breast Cancer Index View

Description: Breast Cancer Index (BCI) Registry Study (BTX-BCI-016-PRT)

Indication: Breast Cancer

Location: Texas Oncology-Grapevine

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Hematologic

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV

Title: PATHFINDER 2 Early Detection Test View

Description: The PATHFINDER 2 Study: Evaluating the Safety and Performance of the GRAIL Multi-Cancer Early Detection Test in an Eligible Screening Population (GRAIL-012)

Indication: Solid Tumors

Location: Texas Oncology-Fort Worth Cancer Center

Phase: IV